Top Medical News
Yesterday
In patients with chronic hepatitis B (CHB) infections on nucleos(t)ide analogue (NA) treatment, normal on-treatment alanine aminotransferase levels are associated with lower risks of hepatic events, a recent study has shown.
4 days ago
Monoprophylaxis with entecavir (ETV) or tenofovir (TDF) following a 6-month combination therapy regimen of hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogues can prevent recurrence of hepatitis B virus (HBV) infection, a recent study has shown.
Saras Ramiya, 6 days ago
The non-invasive biomarker PRO-C3 can determine the presence of advanced liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD), a study shows.
18 Sep 2018
Patients positive for hepatitis B virus (HBV) infection are at higher risk of advanced colorectal adenoma, a recent study has shown.
Saras Ramiya, 18 Sep 2018
Caspase-2, a protein-cleaving enzyme, is a key component in the onset and progression of non-alcoholic steatohepatitis (NASH), a new study shows.
06 Sep 2018
Oral supplementation with taurine is safe and effective in the management of muscle cramps in patients with chronic liver disease, yielding significant reductions in the frequency, duration and intensity of cramps, according to a study.
05 Sep 2018
The risk of long-term and recurrent thrombotic events is elevated in cirrhotic patients with splanchnic vein thrombosis, a recent study has found.
Special Reports
04 Dec 2017
Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.
14 Dec 2016
At the recent Annual Scientific Congress of the Malaysian Society of Gastroenterology and Hepatology (GUT 2016), held at Shangri-La Hotel, Kuala Lumpur, an expert from Hong Kong spoke on the role of direct-acting antivirals as well as pan-genotypic agents that are set to revolutionize hepatitis C treatment.
01 Dec 2016
An expert panel meeting on hepatorenal syndrome (HRS) was recently convened in Kuala Lumpur with the aim of discussing management practices in different hospital settings. Chaired by Professor Sanjiv Mahadeva, consultant gastroenterologist, University Malaya Medical Centre, the meeting saw local and regional experts share HRS cases they have encountered in their practice.
09 Nov 2016
At a recent Abbott-sponsored satellite symposium held during the GUT Congress 2016 in Kuala Lumpur, an expert from India presented on the management of alcoholic liver disease, and illustrated the role of SAMe as a complementary therapy.
30 Oct 2015
VIEKIRA PAK– ombitasvir, paritaprevir, ritonavir 12.5/7.5/50 mg tab copackaged with dasabuvir 250 mg film-coated tab,an innovative treatment for genotype 1 chronic hepatitis C.
Conference Reports
Christina Lau, 22 Feb 2018

Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.

Roshini Claire Anthony, 19 Feb 2018

Pembrolizumab demonstrated promising results in several outcomes among patients with advanced hepatocellular carcinoma (HCC) whose disease progressed on or who were unable to tolerate treatment with sorafenib, findings from the KEYNOTE-224* trial show.

Jackey Suen, 25 Oct 2017

Eradication of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is becoming achievable, although much work still has to be done, says an expert.

Jackey Suen, 24 Oct 2017

Virtual hepatic venous pressure gradient (vHVPG), a novel noninvasive approach to assess portal hypertension, is shown to correlate well with the gold-standard invasive method in a recent Chinese study.

04 Oct 2017
Slideshow: Highlights from the Asia Pacific Digestive Week 2017 (APDW 2017)
Naomi Rodrig, 03 Oct 2017

An index of three liver-specific microRNAs (the MiR-B Index) could serve as a biomarker of spontaneous or treatment-induced transition from active to inactive chronic hepatitis B virus (HBV) infection, facilitating disease monitoring and testing of new antivirals, according to Dr Mauricia Brunetto from the University of Pisa, Italy, who spoke recently at the Asian Pacific Digestive Week (APDW) 2017 in Hong Kong.

Christina Lau, 03 Oct 2017

A new technology involving the use of monocyte-derived hepatocyte-like (MH) cells has demonstrated high sensitivity and specificity in the diagnosis of idiosyncratic drug-induced liver injury (DILI), data presented at the Asian Pacific Digestive Week (APDW) 2017 held in Hong Kong have shown.

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download